Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis[1]

New England Journal of Medicine

Volumn 372, Issue 6, 2015, Pages 576-577

  Alffenaar, Jan Willem ^a   Gumbo, Tawanda ^b   Aarnoutse, Rob ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; TREATMENT DURATION; TUBERCULOSIS; FEMALE; ISOLATION AND PURIFICATION; MALE; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84922295419     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1414718     Document Type: Letter

References (7)

1. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87.
2. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-7.
3. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27-35.
4. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642-51.
5. [Erratum, J Infect Dis 2004;190:2059.]
6. Alffenaar JW, Van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009;49:1080-2.
7. Pranger AD, Van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011;38:888-94.